Ankylosing spondylitis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• IL-17 3
• TNF 2
• JAK 1
• IL-23 1
• NLRP3 0
• STAT3 0
• TLR4 0
• COX-2 0
• IL-6 0
• MAPK 0
• NRF2 0
• PD-1 0
• AKT 0
• AXL 0
• BDNF 0
• CD40 0
• CGRP 0
• CXCR4 0
• ERK 0
• FAK 0
• G6PD 0
• HIF-1 0
• IL-1 0
• IL-15 0
• MEK 0
• NF1 0
• PD-L1 0
• PI3K 0
• PIK3CA 0
• PPAR 0
• PTEN 0
• RANKL 0
• VEGF 0

5 of 5+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R56

  Identifying pre-osteoarthritis endotypes and mechanisms

  Hebrew Rehabilitation Center for Aged· Boston, United States· US$604,389 awarded in fiscal year 2026· until Aug 2027

• NIH NIAMS · R01

  Defining Early Events in the Pathogenesis of Axial Spondyloarthritis

  Washington University· Saint Louis, United States· US$546,057 awarded in fiscal year 2026· until Aug 2031

• NIH NIAID · R03

  Understanding the Development of Human Type 17 CD8 T Cells

  Washington University· Saint Louis, United States· US$77,750 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · K08

  Use of Antenatal Disease Modifying Antirheumatic Drugs and Maternal-child Health Among Women with Chronic Inflammatory Arthritis

  Yale University· New Haven, United States· US$160,024 awarded in fiscal year 2026· until Aug 2031

• NIH NIAMS · K23

  Tailored Exercise Interventions for Patients with Axial Spondyloarthritis: Targeting Sex-Based Challenges to Improve Clinical Outcomes

  University of Washington· Seattle, United States· US$169,668 awarded in fiscal year 2026· until Apr 2031

• European Commission (Horizon Europe) · HORIZON-IA

  CANVAS: STREET FURNITURE AS A CANVAS - BEAUTY, INCLUSION AND SUSTAINABILITY IN PUBLIC SPACE

  Ait Austrian Institute of Technology Gmbh· Wien, Austria· EU contribution €5,110,818· until Aug 2030· 10 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE BLINDED RANDOMIZED CONTROLLED TRIAL (PRoRota)

  Universitetet I Bergen· Bergen, Norway· EU contribution €5,299,999· until Apr 2030· 4 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  NEXT-GENERATION SCALABLE AEM ELECTROLYZERS AS SUSTAINABLE HYDROGEN PRODUCTION SYSTEM (NEREUS)

  Antares Electrolysis S.r.l.· Genova, Italy· EU contribution €3,999,786· until Feb 2029· 7 countries

• European Commission (Horizon Europe) · HORIZON-CSA

  OPERATING OPEN RESEARCH EUROPE AS A NON-PROFIT OPEN ACCESS SCIENTIFIC PUBLISHING SERVICE FOR THE PUBLIC GOOD (ORE 2.0)

  Organisation Europeenne Pour la Recherche Nucleaire· Geneve 23, Switzerland· EU contribution €9,996,090· until Dec 2030

• European Commission (Horizon Europe) · HORIZON-RIA

  CARBON-NEUTRAL PRODUCTION AND DIRECT FUEL-CELL DEPLOYMENT OF ISOPROPANOL AS ENERGY CARRIER (IsoPROPEL)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €3,995,636· until Apr 2029· 8 countries

10 of 44 running projects, newest first. Listed amounts together: US$10.9m + €89.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Mendelian Randomization Analysis 20
• Gene Expression Profiling 12
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 9
• Metabolomics 5
• Flow Cytometry 3
• Magnetic Resonance Imaging 72
• Machine Learning 10
• Deep Learning 8
• Cohort Studies 24
• Genome-Wide Association Study 24

• Association of 14 matrix metalloproteinases and 4 tissue inhibitors of metalloproteinases on ankylosing spondylitis: A bidirectional Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• Association between ankylosing spondylitis and hearing loss: A Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• Inherited predisposition to increased systemic inflammation predicts a broad class of disease phenotypes.

  HGG Adv, Sept 2026

• Association between inflammatory bowel disease and ankylosing spondylitis: Mendelian randomization of a different database and meta-analysis.

  Medicine (Baltimore), Jul 2026

• Rheumatoid arthritis susceptibility genes show pathotype-specific expression in synovial tissue of patients with early treatment-naïve RA.

  Ann Rheum Dis, Jul 2026

• Ten millennia of purifying selection on HLA-B27 reveals an ancient epidemic-scale burden of spondyloarthritis in West Eurasia.

  Autoimmun Rev, Jul 2026

• Cross-trait mapping of shared susceptibility across inflammatory bowel disease and spondyloarthropathies.

  J Transl Med, Jun 2026

• Multi-layered functional genomics prioritizes candidate effectors and regulatory mechanisms of ankylosing spondylitis.

  Front Immunol, Jun 2026

• Exploring causal associations between autoimmune diseases and hearing loss: a mendelian randomization study.

  Braz J Otorhinolaryngol, May 2026

• Uncovering Causal Links Between Autoimmune Diseases and Muscular Dystrophy: A Bidirectional Mendelian Randomization Study.

  OMICS, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.